Table 2.
HLA-G alleles, low-resolution groups and genotypes as related to outcomes of the genital and oral HPV infections during the six-year follow-up
| Genital HPV infection outcomes1 | Oral HPV infection outcomes1 | |||||||
|---|---|---|---|---|---|---|---|---|
| HLA-G | Always negative (n = 106) |
Incidence (n = 200) |
Clearance (n = 57) |
Persistence (n = 143) |
Always negative (n = 205) |
Incidence (n = 101) |
Clearance (n = 27) |
Persistence (n = 74) |
| Alleles | OR (95% CI) | OR (95% CI) | ||||||
| *01:01:01 | 0.99 (0.45–2.19) | 0.72 (0.37–1.40) | 1.14 (0.61–2.12) | 0.81 (0.44–1.50) | 1.14 (0.62–2.10) | 1.14 (0.59–2.21) | 1.92 (0.86–4.29) | 0.68 (0.34–1.32) |
| *01:01:02 | 1.06 (0.59–1.92) | 1.08 (0.67–1.75) | 0.88 (0.55–1.40) | 1.06 (0.67–1.67) | 1.20 (0.76–1.90) | 0.87 (0.53–1.42) | 0.50 (0.29–0.79) | 0.96 (0.56–1.65) |
| *01:01:03 | 1.13 (0.44–2.91) | 1.26 (0.56–2.87) | 1.18 (0.54–2.64) | 1.34 (0.63–2.85) | 0.55 (0.25–1.21) | 1.90 (0.89–4.07) | 1.07 (0.46–2.51) | 1.16 (0.49–2.72) |
| *01:03:01 | 1.12 (0.23–5.42) | 0.79 (0.22–2.86) | 1.14 (0.32–4.13) | 2.75 (0.70–10.82) | 4.22 (0.88–20.22) | 0.50 (0.10–2.39) | NC | 0.34 (0.04–2.72) |
| *01:04:01 | 0.98 (0.47–2.03) | 0.78 (0.44–1.38) | 1.08 (0.61–1.91) | 0.81 (0.46–1.43) | 1.74 (0.98–3.09) | 0.54 (0.28–1.04) | 0.66 (0.33–1.33) | 0.92 (0.47–1.78) |
| *01:06 | 0.44 (0.05–3.48) | 2.45 (0.52–11.55) | 1.34 (0.38–4.68) | 0.64 (0.18–2.24) | 0.57 (0.16–1.98) | 1.17 (0.33–4.08) | 1.10 (0.28–4.25) | 1.84 (0.52–6.46) |
| Groups2 | ||||||||
| G01:01 | 0.89 (0.10–8.16) | 1.26 (0.21–7.68) | 0.32 (0.04–2.94) | 0.58 (0.95–3.52) | 1.49 (0.25–9.05) | 0.74 (0.12–4.47) | 1.38 (0.15–12.49) | 0.47 (0.77–2.88) |
| G04:01 | 0.93 (0.45–1.92) | 8.83 (0.47–1.47) | 1.06 (0.60–1.87) | 0.89 (0.51–1.55) | 1.87 (1.06–3.30) | 0.51 (0.27–0.98) | 0.63 (0.32–1.26) | 0.87 (0.45–1.69) |
| Genotypes | ||||||||
| 010101:010101 | 1.25 (0.68–2.29) | 1.19 (0.71–1.99) | 1.01 (0.61–1.65) | 0.87 (0.54–1.41) | 0.54 (0.33–0.88) | 1.49 (0.90–2.47) | 1.18 (1–28-3.71) | 1.44 (0.83–2.49) |
| 010101:010102 | 1.22 (0.64–2.29) | 0.79 (0.47–1.33) | 1.09 (0.66–1.84) | 0.89 (0.54–1.47) | 1.37 (0.83–2.28) | 0.90 (0.52–1.55) | 0.62 (0.33–1.51) | 0.75 (0.41–1.38) |
| 010101:010103 | 0.51 (0.11–2.26) | 2.99 (0.85–10.49) | 1.09 (0.40–2.94) | 1.61 (0.63–4.13) | 0.57 (0.22–1.49) | 1.91 (0.75–4.85) | 1.05 (0.36–3.01) | 1.49 (0.54–4.06) |
| 010101:010401 | 0.99 (0.43–2.27) | 0.59 (0.31–1.12) | 0.95 (0.50–1.82) | 0.68 (0.35–1.31) | 2.18 (1.12–4.26) | 0.64 (0.31–1.32) | 0.97 (0.46–2.03) | 0.45 (0.18–1.11) |
| 010102:010102 | 0.49 (0.06–3.92) | 1.25 (0.32–4.92) | 0.60 (0.16–2.27) | 1.14 (0.32–4.04) | 0.67 (0.18–2.41) | 0.87 (0.22–3.42) | 1.26 (0.32–5.01) | 1.36 (0.34–5.39) |
| 010102:010401 | 0.44 (0.05–3.48) | 5.53 (0.70–43.77) | 0.91 (0.27–3.04) | 1.38 (0.41–4.63) | 0.84 (0.25–2.81) | 0.20 (0.02–1.54) | NC | 4.01 (1.19–13.53) |
1HPV outcomes definitions: incidence: baseline negative and acquired a HPV infection during follow-up, clearance: HPV positive and cleared the HPV (staying HPV negative to the end of the follow-up): persistence: recoded two or more consequence visit as HPV positive during the follow-up. 2Groups as low resolution for the following alleles G01:01: *010101, *010102, *010103, *010114 and G04:01: *01040 and *010404. Only those HLA-G alleles and genotypes that where > 3% prevalent among the women where included to the analyses. NC: Not Computable. The significant associations are bolded